Valuation: Carmat SA

Market Cap 6.15M 6.96M 5.82M 5.25M 9.91M 667M 10.03M 69.68M 26.8M 342M 26.14M 25.57M 1.1B P/E 2023
-3.09x
P/E 2024 -0.95x
Enterprise Value 59.25M 67.13M 56.08M 50.61M 95.52M 6.43B 96.65M 672M 258M 3.3B 252M 246M 10.57B EV / Sales 2023
56.1x
EV / Sales 2024 13.5x
Free-Float
89.06%
Yield 2023 *
-
Yield 2024 -
Current year 0.1
Extreme 0.099
0.1
1 year 0.1
Extreme 0.099
0.1
3 years 0.08
Extreme 0.085
9.99
5 years 0.08
Extreme 0.085
29.5
10 years 0.08
Extreme 0.085
40.06
Manager TitleAgeSince
Chief Executive Officer 55 2016-08-31
Director of Finance/CFO - 2018-12-11
Chief Tech/Sci/R&D Officer - 2025-03-31
Director TitleAgeSince
Director/Board Member 55 -
Director/Board Member 68 2017-01-01
Director/Board Member 79 2017-04-19
Date Insider Type Main position Quantity % Market Cap. Importance
3/13/25 Sell

Chairman

1,343,333 2.3347%
3/13/25 Buy

Chairman

1,343,333 2.3347%
5/29/24 Buy

Director

1,343,333 4.6122%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-97.87% 7.08M
-2.10%-4.69%-25.75%+2.04% 175B
-0.92%-4.94%-8.17%+10.12% 111B
-0.90%+0.11%-25.55%+0.78% 107B
+0.69%+0.76%-47.04%-11.84% 75.31B
-2.39%-4.51%-2.54%+66.83% 58.7B
-1.63%-2.19%-2.72%-30.76% 49.57B
+1.53%+4.31%+15.99%+53.87% 49.27B
-2.11%+0.13%-17.19%+19.42% 42.02B
-0.40%-3.62%+29.84%-7.51% 32.69B
Average -0.49%-0.62%-8.31%+0.51% 70.06B
Weighted average by Cap. -0.27%-1.13%-15.59%+8.99%

Financials

2023 2024
Net sales 3.84M 4.35M 3.63M 3.28M 6.19M 417M 6.26M 43.5M 16.73M 214M 16.32M 15.96M 684M 7.34M 8.32M 6.95M 6.27M 11.84M 798M 11.98M 83.27M 32.02M 409M 31.24M 30.55M 1.31B
Net income -53.87M -61.03M -50.99M -46.02M -86.85M -5.85B -87.88M -611M -235M -3B -229M -224M -9.61B -51.4M -58.23M -48.65M -43.9M -82.86M -5.58B -83.84M -583M -224M -2.86B -219M -214M -9.17B
Net Debt 49.64M 56.24M 46.98M 42.4M 80.03M 5.39B 80.97M 563M 216M 2.76B 211M 207M 8.85B 53.1M 60.16M 50.26M 45.36M 85.61M 5.77B 86.62M 602M 232M 2.96B 226M 221M 9.47B
Logo Carmat SA
Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.
Employees
153
  1. Stock Market
  2. Stocks
  3. ALCAR Stock